Tango Therapeutics
$20.06
5
+$0.26+1.31% Today
Statistics
Day High
20.54
Day Low
19.62
52W High
22.2
52W Low
1.03
Volume
2,386,918
Avg. Volume
3,347,996
Mkt Cap
2.7B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.3137
Actual EPS
N/A
Financials
-309.73%Profit Margin
Unprofitable84.14MRevenue
-260.6MNet Income
Analyst Ratings
$21.00Average Price Target
The highest estimate is 30.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy 89%
Hold 11%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TNGX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Editas Medicine
EDIT
Mkt Cap261.32M
Beam Therapeutics
BEAM
Mkt Cap2.51B
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Allogene Therapeutics
ALLO
Mkt Cap604.57M
Fate Therapeutics
FATE
Mkt Cap141.84M
Novartis
NVS
Mkt Cap297.32B
Gilead Sciences
GILD
Mkt Cap173.41B
About
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Show more...
CEO
Dr. Barbara L. Weber M.D.
Employees
155
Country
US
ISIN
US87583X1090
Listings
0 Comments
Share your thoughts
FAQ
What is Tango Therapeutics stock price today?▼
The current price of TNGX is $20.06 USD — it has increased by +1.31% in the past 24 hours. Watch Tango Therapeutics stock price performance more closely on the chart.
What is Tango Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tango Therapeutics stocks are traded under the ticker TNGX.
Is Tango Therapeutics stock price growing?▼
TNGX stock has fallen by -5.47% compared to the previous week, the month change is a +18.35% rise, over the last year Tango Therapeutics has showed a +1,557.85% increase.
What is Tango Therapeutics market cap?▼
Today Tango Therapeutics has the market capitalization of 2.7B
When is the next Tango Therapeutics earnings date?▼
Tango Therapeutics is going to release the next earnings report on May 13, 2026.
What were Tango Therapeutics earnings last quarter?▼
TNGX earnings for the last quarter are -0.29 USD per share, whereas the estimation was -0.32 USD resulting in a +8.86% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tango Therapeutics revenue for the last year?▼
Tango Therapeutics revenue for the last year amounts to 84.14M USD.
What is Tango Therapeutics net income for the last year?▼
TNGX net income for the last year is -260.6M USD.
How many employees does Tango Therapeutics have?▼
As of April 08, 2026, the company has 155 employees.
In which sector is Tango Therapeutics located?▼
Tango Therapeutics operates in the Health Care sector.
When did Tango Therapeutics complete a stock split?▼
Tango Therapeutics has not had any recent stock splits.
Where is Tango Therapeutics headquartered?▼
Tango Therapeutics is headquartered in Boston, US.